Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study

BACKGROUND: Anti-amyloid vaccines may offer a convenient, affordable, and accessible means of preventing and treating Alzheimer's disease. UB-311 is an anti–amyloid-β active immunotherapeutic vaccine shown to be well-tolerated and to have a durable antibody response in a phase 1 trial. This pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Hui Jing, Dickson, Samuel P., Wang, Pei-Ning, Chiu, Ming-Jang, Huang, Chin-Chang, Chang, Chiung-Chih, Liu, Hope, Hendrix, Suzanne B., Dodart, Jean-Cosme, Verma, Ajay, Wang, Chang Yi, Cummings, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338203/
https://www.ncbi.nlm.nih.gov/pubmed/37392597
http://dx.doi.org/10.1016/j.ebiom.2023.104665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338203/
https://www.ncbi.nlm.nih.gov/pubmed/37392597
http://dx.doi.org/10.1016/j.ebiom.2023.104665

Ejemplares similares